New trial aims to tame tough breast cancer with tailored treatments
NCT ID NCT07178730
Summary
This large trial is testing two main ideas for treating aggressive, early-stage triple-negative breast cancer. First, it asks if patients who respond very well to initial chemo can safely skip more of it and go straight to surgery. Second, for patients who don't respond as well, it compares adding a newer targeted drug combo to standard chemo to see if it improves outcomes. The goal is to personalize treatment to be more effective and potentially less burdensome.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.